Parkinson's Disease/Movement Disorders News

SEATTLE — In a first-in-human study, participants with paralysis who received an endovascular brain-computer implant were able to effectively operate a computer, researchers reported at the American Academy of Neurology annual meeting.

Natalia S. Rost, MD, MPH, chair of the AAN science committee, led a discussion to highlight select studies being presented at the AAN’s annual meeting April 2-7 in Seattle.

Older adults had a 16% lower risk for developing parkinsonism after taking statins for 6 years compared with those not on statins, a report published in Neurology showed.

Sage Therapeutics Inc. announced positive results from a phase 2 trial for an oral treatment that was linked to improvements in functioning, learning and memory in those with mild cognitive impairment from Parkinson’s disease.

The American Academy of Neurology noted palliative care can benefit individuals with neurologic diseases and may lead to longer survival when provided early in the disease process.

The FDA has granted an investigational new drug application to 4D pharma plc for two live biotherapeutics to treat Parkinson’s disease, according to a company release.

Avion Pharmaceuticals introduced its Parkinson’s disease treatment, Dhivy, the first carbidopa/levodopa fractional tablet intended to be divided, according to a press release.

Adults with two or more chronic conditions by middle age had an increased risk for dementia later in life, according to findings published in The BMJ.

One-year survivors of MI experienced decreased risk for developing Parkinson’s disease and secondary Parkinsonism compared with the general population, researchers reported.

The National Institute of General Medical Sciences, a division of the NIH, awarded $1.8 million to Integrated Micro-Chromatography Systems Inc. for phase 2 of its fast track Small Business Innovation Research grant, according to a release.